GlassScriptPhysician profile
Bryce Stallings
NPI 1326314188
$16,345.91
in general payments reported to CMS, 2019-2025
33 companies · $5,752 in 2025
The $5,752 reported for 2025 was more than what 99% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,146 · 2022: $1,394 · 2023: $2,857 · 2024: $5,198 · 2025: $5,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,173.18 |
| Education | $633.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,923.85 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,805.79 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $1,692.20 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Incyte Corporation | $1,392.82 | 2021-2025 | Opzelura |
| Amgen INC. | $1,373.24 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $1,131.40 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $854.25 | 2021-2025 | Nemluvio, Twyneo, Aklief |
| Genzyme Corporation | $852.82 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $799.00 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $692.99 | 2022-2025 | Ilumya, Odomzo, Blu-U |
| Arcutis Biotherapeutics, INC. | $644.88 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $574.69 | 2021-2025 | Adbry |
| Pfizer INC. | $411.30 | 2021-2025 | |
| Dermavant Sciences, INC. | $387.34 | 2023-2024 | Vtama |
| Organon LLC | $340.47 | 2025 | Vtama, Nexplanon |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $290.25 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.39 | 2023-2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $265.09 | 2024-2025 | Sotyktu |
| Convatec INC. | $129.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $124.80 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $76.74 | 2021-2025 | Jublia, Cabtreo, Duobrii |
| Biofrontera INC. | $64.07 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Sandoz INC. | $42.05 | 2023-2024 | Hyrimoz |
| Almirall LLC | $40.95 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $34.00 | 2023 | |
| Verrica Pharmaceuticals INC. | $33.27 | 2025 | Ycanth |
| Paratek Pharmaceuticals, INC. | $16.10 | 2024 | Nuzyra |
| Lnhc, INC | $15.64 | 2025 | Zelsuvmi |
| Botanix Sb INC | $15.05 | 2025 | Sofdra |
| Journey Medical Corporation | $14.57 | 2022 | |
| Cashflow Solutions, LLC | $14.16 | 2023 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
| Strata Skin Sciences, INC. | $14.16 | 2022 | |
| Fresenius Kabi USA, LLC | $13.58 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Stallings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.